Add to ORKGCoronavirus 2019 (COVID 19) was first detected in December 2019 in China. It has become a pandemic. With concern about therapies that may decrease immunity and enhance the severity of an individual's COVID-19 infection, leading to a possibly fatal outcome, use of immunosuppressants has become an important concern. This work focuses on management of various skin diseases individuals lacking immunity to COVID-19 but requiring a systemic immunosuppressant, keeping in view the challenge of the COVID 19 pandemic and that our knowledge of this virus and its effects on the immune system are incomplete including knowledge as to an individual's immunity after COVID-19 infection. © 2020 Wiley Periodicals LLC
Introduction. With the onset of the COVID-19 pandemic the dermatological manifestations of the infec...
Background: The earliest cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerg...
Background Few and small studies have described the management of immunomodulant/immunosuppressive t...
Background: Managing patients treated with systemic immunosuppressive and/or biologic therapy (SIBT)...
The Precision Medicine Era has helped to better manage patients with immunological and oncological d...
"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 in Wuhan ...
As the COVID-19 pandemic has rapidly spread around the globe, concern has been raised regarding susc...
The pandemic known as coronavirus disease-19 (COVID-19) has quickly spread worldwide, with a signifi...
Patients on immunomodulators, including biologic agents and new small molecular inhibitors, for cuta...
With the rapid outbreak of the coronavirus disease 2019 (COVID-19) pandemic, considerable concerns a...
Background Few and small studies have described the management of immunomodulant/immunosuppressive t...
COVID‐19, caused by the coronavirus SARS‐CoV‐2, has become pandemic. A further level of complexity o...
An increasing body of evidence has been produced in a very limited period to improve the understandi...
Background: Few and small studies have described the management of immunomodulant/immunosuppressive ...
Introduction. With the onset of the COVID-19 pandemic the dermatological manifestations of the infec...
Introduction. With the onset of the COVID-19 pandemic the dermatological manifestations of the infec...
Background: The earliest cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerg...
Background Few and small studies have described the management of immunomodulant/immunosuppressive t...
Background: Managing patients treated with systemic immunosuppressive and/or biologic therapy (SIBT)...
The Precision Medicine Era has helped to better manage patients with immunological and oncological d...
"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 in Wuhan ...
As the COVID-19 pandemic has rapidly spread around the globe, concern has been raised regarding susc...
The pandemic known as coronavirus disease-19 (COVID-19) has quickly spread worldwide, with a signifi...
Patients on immunomodulators, including biologic agents and new small molecular inhibitors, for cuta...
With the rapid outbreak of the coronavirus disease 2019 (COVID-19) pandemic, considerable concerns a...
Background Few and small studies have described the management of immunomodulant/immunosuppressive t...
COVID‐19, caused by the coronavirus SARS‐CoV‐2, has become pandemic. A further level of complexity o...
An increasing body of evidence has been produced in a very limited period to improve the understandi...
Background: Few and small studies have described the management of immunomodulant/immunosuppressive ...
Introduction. With the onset of the COVID-19 pandemic the dermatological manifestations of the infec...
Introduction. With the onset of the COVID-19 pandemic the dermatological manifestations of the infec...
Background: The earliest cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerg...
Background Few and small studies have described the management of immunomodulant/immunosuppressive t...